Install
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research & Evidence
Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients With IPF
10+ hour, 48+ min ago (324+ words) The trial demonstrated statistical significance for multiple secondary endpoints compared to placebo, including reduced lung fibrosis and increased total lung capacity (TLC) as shown by key measures on quantitative high-resolution computed tomography (HRCT) imaging Patients treated with taladegib experienced an…...
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
1+ mon, 1+ week ago (415+ words) Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today the initiation of Phase…...
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
41+ min ago (473+ words) Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic... Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following…...
Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder
1+ mon, 1+ week ago (252+ words) Clearmind Medicine Inc. (Nasdaq: CMND) announced the initiation of Phase IIa of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of Alcohol Use... Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder StreetInsider.com…...
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
1+ hour, 58+ min ago (294+ words) Rapid-Fire Oral Presentations: Real-World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform Presenter: David Lanfear, M.D., M.S., Chief Scientific Officer of Henry Ford Health, U.S.Date/time: Sunday, October 11 at 11:30 am MST Early eGFR…...
OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global Meeting
3+ day, 9+ hour ago (331+ words) Initial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06 At the September 23, 2026, data cutoff, CUSP06 achieved a 62% objective response rate (ORR) in patients treated at 4.0mg/kg in Phase 1b with response and durability data…...
Why Aren't Advanced Cancer Patients Participating in Clinical Trials?
3+ hour, 21+ min ago (374+ words) — Trial participation increasingly driven by factors at the physician and practice levels Participation in clinical trials among patients with advanced cancers has modestly increased over time, but remains low, with a minority of physicians and practices accounting for most enrollments,…...
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
3+ week, 3+ day ago (422+ words) Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE)…...
Roche Outlines Positive Phase 3 Trial Data for Small-cell Lung Cancer Treatment in China
3+ hour, 17+ min ago (83+ words) Roche's collaborator MediLink said the randomized phase III Taishan-302 trial evaluating Tam-Peli in Chinese patients with relapsed small-cell lung cancer achieved its primary endpoint of overall... Roche Outlines Positive Phase 3 Trial Data for Small-cell Lung Cancer Treatment in China Published…...
6 Treatment Outcomes of the KEYNOTE-522 Regimen in an Ethnically Diverse Patient Population
3+ hour, 20+ min ago (305+ words) CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers. Background As a result of the KEYNOTE-522 trial demonstrating improved pathologic complete response (pCR) rates with the addition of pembrolizumab…...